2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5534 Avapritinib treatment in systemic mastocytosis with an associated chronic myelomonocytic leukemia: Outcomes from PATHFINDER

Tracy George, MD, Deepti H. Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed2, Michael Deininger, MD, PhD3, Jason Gotlib4, Daniel J DeAngelo, MD, PhD5, Andreas Reiter V, MD6, Ilda Bidollari, MD, MBA7, Guang Yang, PhD8, Aaron Zakharyan, PhD9, Saša Dimitrijevic, PhD10, Amber King, PharmD, BCOP11, Johannes Luebke, MD12
1 ARUP Laboratories, University of Utah, Salt Lake City, Utah, United States
2 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
3 University of Michigan, Ann Arbor, Michigan, United States
4 Stanford Cancer Institute/Stanford University School of Medicine, Stanford, California, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 University Hospital Mannheim, Heidelberg University, Mannheim, Germany
7 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
8 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
9 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
10 Blueprint Medicines (Switzerland) GmbH, Zug, Switzerland
11 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
12 University Hospital Mannheim, Heidelberg University, Mannheim, Germany

Introduction:

Systemic mastocytosis (SM) is driven predominantly by the KIT D816V mutation. In patients with advanced SM (AdvSM), associated hematologic neoplasms, most commonly chronic myelomonocytic leukemia (CMML), are often present. The pathogenetic basis of SM–CMML is the multilineage involvement of the KIT mutation and additional somatic mutations, which occurs in ~95% of patients with SM. Patients who are initially diagnosed with CMML are not routinely evaluated for SM, although the KIT D816V mutation was detected via digital droplet polymerase chain reaction (ddPCR) in approximately 20% of patients in a recent multicenter, retrospective cohort study of patients with pathologically confirmed CMML. Patients with SM–CMML may benefit from the selective KIT D816V inhibitor avapritinib, which has demonstrated clinical benefit and is approved for treatment of adult patients with AdvSM.

Methods:

Outcomes were assessed in patients with SM–CMML receiving avapritinib in the PATHFINDER study (NCT03580655), an international, multicenter, open-label, single-arm phase 2 clinical trial assessing the efficacy and safety of avapritinib in adults with centrally confirmed AdvSM. Responses to treatment were assessed using the modified International Working Group-Myeloproliferative Neoplasms Research and Treatment-European Competence Network on Mastocytosis (mIWG-MRT-ECNM) criteria. Additionally, mutational profile and measures of disease burden, including monocyte count, KIT D816V variant allele frequency (VAF), serum tryptase, and spleen volume, were evaluated.

Results:

Of the 107 patients enrolled in PATHFINDER, 31 (29%) had SM–CMML, centrally adjudicated as CMML-0 in 25 (81%) patients and CMML-1 in 6 (19%) patients by 4th edition WHO criteria, and as CMML-1 in all 31 patients by 5th edition criteria. In total, 18/31 patients (58%) were male, and the median (range) age was 71 years (47–86 years). Myelodysplastic and myeloproliferative CMML were diagnosed in 21/31 (68%) and 10/31 (32%) patients, respectively, based on a white blood cell cutoff of 13 × 109/L. Two patients (6%) had previously been treated with hypomethylating agents and two (6%) with hydroxyurea; one previously treated patient (3%) had received both. KIT D816V mutations were detected by ddPCR in 30/31 (97%) patients. Next-generation sequencing with TruSight Myeloid panel (Illumina, San Diego, CA, USA) in 30 patients detected additional mutations in genes: TET2 (80%), SRSF2 (50%), ASXL1, RUNX1 (23%), EZH2, BCOR (20%), BCORL1, GATA2, NRAS (17%), CDKN2A, CUX1, IDH2, TP53 (13%), CBL, CBLC, CEBPA, IKZF1, KRAS (10%), JAK2 (7%), and the following mutations were found in 3% of patients: ATRX, DNMT3A, GATA1, GNAS, NPM1, PHF6, SETBP1, and SF3B1. At baseline, median (range) values for absolute monocyte count were 1.99 × 109/L (0.90−6.90 × 109/L) (n=30), serum tryptase 181 ng/mL (37−856 ng/mL), KIT D816V VAF 10.67% (0.01−46.68%), and spleen volume 784 mL (150−2219 mL). The median (range) duration of follow-up was 39 months (6−55 months).

Among 27 (87%) mIWG-MRT-ECNM response-evaluable patients, the overall response rate was 20/27 (74%), including complete response (CR), CR with partial hematologic recovery, partial response, and clinical improvement in 4/27 (15%), 3/27 (11%), 11/27 (41%), and 2/27 (7%) of patients, respectively. Compared with baseline, treatment with avapritinib led to median (range) percentage changes in absolute monocyte count of −81% (–99% to 32%), serum tryptase −93% (−99% to −9%), KIT D816V VAF −96% (–100% to 0%), and spleen volume −51% (–96% to 52%) (n=25), based on lowest recorded values. Safety of the overall PATHFINDER population is well characterized with no new concerns.

Conclusions:

Avapritinib demonstrated clinical benefit across multiple measures of disease burden in patients with SM–CMML, consistent with previously reported data in the overall PATHFINDER population. These findings highlight the importance of evaluating for concomitant SM in patients with CMML, as they demonstrate clinical activity of avapritinib in this subset of patients.

Tracy George, MD: Incyte - Consultancy (Includes expert testimony); Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony)